Drugs / Tetracosactide
Tetracosactide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02813655 | Oct 2016 → Nov 2022 | intracranial hypotension | Hospices Civils de Lyon | Terminated | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01371526 | Sep 2010 → Sep 2012 | autoimmune primary adrenal insufficiency | Newcastle University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03514589 Comparator | Oct 2012 → Dec 2025 overdue | adrenocortical insufficiency | Sheffield Children's NHS Foundation Trust | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetracosactide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02813655 ↗ |
| Known as | ACTH1-24 | “We aimed to determine whether tetracosactide (synthetic ACTH1-24) could revive adrenal steroidogenic function in autoimmune Addison's disease.” PMID 24170102 ↗ Dec 2013 |
| Known as | Synacthen | “The aim of this study is to assess the efficacy and safety of tetracosactide (Synacthen®), a synthetic analogue of ACTH, for PDPH treatment in patients who receive neuraxial...” PMID 31915040 ↗ Jan 2020 |
| Known as | Synacthène | “Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.” NCT02813655 ↗ |
| Route | Subcutaneous | “1mg, 3x weekly by sc injection” NCT01371526 ↗ |